Navigation Links
Cardiolipin Antibodies, IgG, IgM, & IgA

ProductsCardiolipin Antibodies, IgG, IgM, & IgA
Company ARUP Laboratories
Item Cardiolipin Antibodies, IgG, IgM, & IgA
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. ImmuLisa™ IgA-ACA anti-Cardiolipin Antibody (ACA) Kit
2. ImmuLisa™ IgG-ACA anti-Cardiolipin Antibody (ACA) Kit
3. ImmuLisa™ IgM-ACA anti-Cardiolipin Antibody (ACA) Kit
4. ImmunoWELL Cardiolipin Antibody (IgG) Test
5. ImmunoWELL Cardiolipin Antibody (IgM) Test
6. Anti-Cardiolipin Antibodies, IgG & IgM
7. Anti-Cardiolipin Antibody, IgG
8. Anti-Cardiolipin Antibody, IgM
9. Cardiolipin IgA II
10. Cardiolipin IgG II
11. Cardiolipin IgM II
Plus cylinders only trial lens set....
Trial Lens Sets....
70 discs to investigate acquired color deficiency. Quantifies neutral zone characteristics of dyschromatopsia and evaluates the relative luminance....
... test (P/N LD15C) include a durable laminated ... P/N LD15C also includes a Plexiglas Case ... for the test subjects fingers ( to ... discs). Beware that these finger cots are ...
Medicine Products:
(Date:5/4/2015)... 2015 “ LiveSchool ” was featured ... takes a look at the latest and coolest applications ... Toohey, the host of AppWatch and technology expert, conducted ... application allows teachers to reward students with good behavior. ... especially in the classroom. And the good people ...
(Date:5/4/2015)... TROY Healthcare Solutions is proud to be a ... (RUG) Conference in Baltimore, MD from May 11 – ... provides an opportunity for clients to gather to network, ... In addition to sponsoring the event, TROY Healthcare Solutions ... Conference. Attendees can stop by the TROY booth and ...
(Date:5/4/2015)... The Lymphoma Research Foundation (LRF) – the ... lymphoma research and serving the lymphoma community through a ... services – is set to host its annual Ace ... Orange, NJ on June 1, 2015. Since 2010, the ... through LRF. , This year, the Lymphoma Research Foundation ...
(Date:5/4/2015)... May 04, 2015 The American Telemedicine ... state policy reports which identify gaps in coverage and ... ATA issued the State Telemedicine Gaps Reports last September, ... their laws and regulations impact healthcare delivery in their ... result of state actions across the nation, ATA reevaluated ...
(Date:5/4/2015)... May 04, 2015 The opportunity for children ... life are the motivating forces behind The Fairy Godmother Next ... and author Amy L. Stark. , The inspiration for the ... next door comes from Stark’s desire to be a fairy ... a fairy godmother to my neighbors’ children since they were ...
Breaking Medicine News(10 mins):Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2
... Ustekinumab injections every 3 months a more convenient ... News) -- The drug ustekinumab has been shown to ... moderate-to-severe psoriasis in two studies published in this week,s ... by binding to two interleukins, proteins produced by the ...
... leadership in proposing prescription,drug marketing reform and transparency, ... believes,New York has a paramount interest in passing ... undue influence that,pharmaceutical companies have over prescribing decisions ... treatment they receive., The reforms include banning ...
... worldwide cancer incidence, researchers at the Moores Cancer Center ... Department of Family and Preventive Medicine have shown a ... ultraviolet B (UVB), and breast cancer. , UVB ... This form of vitamin D also is available through ...
... May 15 Pharmasset, Inc.,(Nasdaq: VRUS ), ... and commercializing novel drugs to treat viral,infections, reported ... March 31, 2008. Pharmasset reported a net loss ... per share for the,quarter ended March 31, 2008, ...
... The following is a,statement from Larry Minnix, President ... Aging:, "Today,s GAO report points out yet again ... of nursing homes in this country. If,we want to ... need to,rethink our approach from the bottom up., ...
... Theranostics Health (THX) today,announced that it ... agreement with Duke University. This relationship will,provide ... technologies: Laser,Capture Microdissection (LCM) and Reverse Phase ... technologies provides a powerful,mechanism to accurately and ...
Cached Medicine News:Health News:Drug Works Well for Moderate-to-Severe Psoriasis 2Health News:AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency 2Health News:UCSD researchers show link between vitamin D status, breast cancer 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8Health News:Theranostics Health Signs Research Collaboration Agreement 2
(Date:5/4/2015)... May 4, 2015   HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of advanced ... Godshall , is scheduled to present at the Bank of ... Las Vegas on Thursday, May 14, 2015, at ... webcast of the Company,s presentation at the conference will be ...
(Date:5/4/2015)... 4, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXI Rx ... of the agreement, Isis is eligible to receive up ... $100 million up-front payment and a $55 million payment ... study in patients with compromised kidney function. Isis is ...
(Date:5/4/2015)... , May 4, 2015 MEI Pharma, ... focused on the clinical development of novel therapies ... mitochondria-specific effects of the Company,s investigational drug candidate ... activity when combined with a tyrosine-kinase inhibitor (TKI). ... to be a potent inhibitor of mitochondrial oxidative ...
Breaking Medicine Technology:HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5